156 related articles for article (PubMed ID: 24650701)
1. Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers.
Bonnet M; Hong CR; Gu Y; Anderson RF; Wilson WR; Pruijn FB; Wang J; Hicks KO; Hay MP
Bioorg Med Chem; 2014 Apr; 22(7):2123-32. PubMed ID: 24650701
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers.
Liew LP; Shome A; Wong WW; Hong CR; Hicks KO; Jamieson SMF; Hay MP
Molecules; 2023 May; 28(11):. PubMed ID: 37298933
[TBL] [Abstract][Full Text] [Related]
3. Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides.
Bonnet M; Hong CR; Wong WW; Liew LP; Shome A; Wang J; Gu Y; Stevenson RJ; Qi W; Anderson RF; Pruijn FB; Wilson WR; Jamieson SMF; Hicks KO; Hay MP
J Med Chem; 2018 Feb; 61(3):1241-1254. PubMed ID: 29253343
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility.
Hay MP; Lee HH; Wilson WR; Roberts PB; Denny WA
J Med Chem; 1995 May; 38(11):1928-41. PubMed ID: 7783125
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers.
Hay MP; Wilson WR; Moselen JW; Palmer BD; Denny WA
J Med Chem; 1994 Feb; 37(3):381-91. PubMed ID: 8308864
[TBL] [Abstract][Full Text] [Related]
6. Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers.
Hong CR; Wang J; Hicks KO; Hay MP
Adv Exp Med Biol; 2016; 899():269-90. PubMed ID: 27325273
[TBL] [Abstract][Full Text] [Related]
7. [Synthesis of 1-substituted nitroimidazoles and its evaluation as radiosensitizing agents].
Adams DR; Martul R; Alvarez MV; López Zumel MC; Espada M
Acta Cient Venez; 1991; 42(5):257-65. PubMed ID: 1843567
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma targeting agents: conjugates of nitroimidazoles with trimethyl nordihydroguaiaretic acid.
Hsu MH; Wu SC; Pao KC; Unlu I; Gnabre JN; Mold DE; Huang RC; Hwu JR
ChemMedChem; 2014 May; 9(5):1030-7. PubMed ID: 24648164
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis inhibitor TX-1898: syntheses of the enantiomers of sterically diverse haloacetylcarbamoyl-2-nitroimidazole hypoxic cell radiosensitizers.
Jin CZ; Nagasawa H; Shimamura M; Uto Y; Inayama S; Takeuchi Y; Kirk KL; Hori H
Bioorg Med Chem; 2004 Sep; 12(18):4917-27. PubMed ID: 15336271
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, transportability and hypoxiaselective binding of 1-beta-D-(5-Deoxy-5-fluororibofuranosyl)-2-nitroimidazole (beta-5-FAZR), a configurational isomer of the clinical hypoxia marker, FAZA.
Emami S; Kumar P; Yang J; Kresolic Z; Paproski R; Cass C; McEwan AJ; Wiebe LI
J Pharm Pharm Sci; 2007; 10(2):237-45. PubMed ID: 17706182
[TBL] [Abstract][Full Text] [Related]
11. Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore.
Papadopoulou MV; Bloomer WD
Anticancer Drugs; 2009 Jul; 20(6):493-502. PubMed ID: 19430289
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, anticancer and radiosensitizing evaluation of some novel sulfonamide derivatives.
Ghorab MM; Ragab FA; Heiba HI; El-Gazzar MG; Zahran SS
Eur J Med Chem; 2015 Mar; 92():682-92. PubMed ID: 25618015
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of a novel nitroimidazole-spermidine derivative as a tumor-targeted hypoxia-selective cytotoxin.
Papadopoulou MV; Rosenzweig HS; Bloomer WD
Bioorg Med Chem Lett; 2004 Mar; 14(6):1519-22. PubMed ID: 15006394
[TBL] [Abstract][Full Text] [Related]
14. In vitro hypoxic cytotoxicity and hypoxic radiosensitization. Efficacy of the novel 2-nitroimidazole N,N,N-tris[2-(2-nitro-1H-imidazol-1-yl)ethyl]amine.
Langenbacher M; Abdel-Jalil RJ; Voelter W; Weinmann M; Huber SM
Strahlenther Onkol; 2013 Mar; 189(3):246-54. PubMed ID: 23361139
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
Papadopoulou MV; Rosenzweig HS; Bloomer WD
Bioorg Med Chem Lett; 2004 Mar; 14(6):1523-5. PubMed ID: 15006395
[TBL] [Abstract][Full Text] [Related]
16. Radiosensitizers of hypoxic mammalian cells. 1-(Hydroxyaminoalkyl)-substituted nitroimidazoles.
Ahmed I; Stratford IJ; Jenkins TC
Arzneimittelforschung; 1985; 35(12):1763-8. PubMed ID: 4096727
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-specific inhibition of recovery from radiation damage by a novel 2-nitroimidazole with a theophylline side chain.
Hodgkiss RJ; Kelleher E; Parrick J
Int J Radiat Biol; 1992 Jun; 61(6):797-803. PubMed ID: 1351530
[TBL] [Abstract][Full Text] [Related]
18. DNA-targeted 2-nitroimidazoles: studies of the influence of the phenanthridine-linked nitroimidazoles, 2-NLP-3 and 2-NLP-4, on DNA damage induced by ionizing radiation.
Buchko GW; Weinfeld M
Radiat Res; 2002 Sep; 158(3):302-10. PubMed ID: 12175307
[TBL] [Abstract][Full Text] [Related]
19. New antimetastatic hypoxic cell radiosensitizers: design, synthesis, and biological activities of 2-nitroimidazole-acetamide, TX-1877, and its analogues.
Kasai S; Nagasawa H; Yamashita M; Masui M; Kuwasaka H; Oshodani T; Uto Y; Inomata T; Oka S; Inayama S; Hori H
Bioorg Med Chem; 2001 Feb; 9(2):453-64. PubMed ID: 11249137
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
